Our study of CY as a prototype of DNA/HDAC dual-targeting drug demonstrates that by incorporating small enzyme inhibitory moiety into traditional DNA-damaging drugs, we can achieve higher toxicity against cancer cells. Here, HDAC9 is linked to cancer.